Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 13/20 | 0.73 |
| ▸ | PDK2 | Q15119 | 13/20 | 0.73 |
| ▸ | PDK3 | Q15120 | 13/20 | 0.73 |
| ▸ | PDK4 | Q16654 | 13/20 | 0.73 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.66 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568116 | 1.00 | PDK1 (0.73) | PDK1PDK2PDK3PDK4NR1H2 | |
| SCHEMBL6569823 | 0.87 | PDK1 (0.86) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6569819 | 0.87 | PDK1 (0.86) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6570006 | 0.86 | PDK1 (0.77) | PDK1PDK2PDK3PDK4NR1H2 | |
| SCHEMBL6570001 | 0.86 | PDK1 (0.77) | PDK1PDK2PDK3PDK4NR1H2 | |
| SCHEMBL4609853 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4NR1H2 | |
| SCHEMBL6571201 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6568184 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL4608280 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4NR1H2 | |
| SCHEMBL6571208 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8692001-B2 | Sulfonamides for the modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2014-04-08 | — | — | US | disclosed |
| US-8692001-B2 | Sulfonamides for the modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2014-04-08 | — | — | US | disclosed |
| WO-2012056319-A1 | SULFONAMIDES FOR THE MODULATION OF PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | US | disclosed |
| EP-1082110-B1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | PDK1, PDK4, PDK2 | PDK1 1/4885PDK2 3/4885PDK3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.